FDA Guidance Outlines CMC Requirements for Cell-Based Cardiovascular Therapies
The US Food and Drug Administration has released a new draft guidance on somatic cell therapies that are designed to advance the treatment of heart disease through the regeneration of cardiac tissues.
The US Food and Drug Administration has released a new draft guidance on somatic cell therapies that are designed to advance the treatment of heart disease through the regeneration of cardiac tissues. The document includes information on preclinical testing, evaluating delivery systems, clinical trial design, and chemistry, manufacturing, and controls (CMC) information required.
As for other types of cellular products, cell therapies for cardiac disease should include detailed descriptions of and data about the cell source, collection methods, processing methods, ancillary materials, formulation, testing methods, product release criteria, storage and shipping conditions, stability, segregation procedures to prevent cross contamination, and container labeling (in process and final product).
The guidance notes that if antibodies are used during processing to select cell populations enriched for a specific cell surface antigen, those antibodies should be demonstrated to be free of adventitious agents and of appropriate quality to function as intended.
The document also says that sufficient testing must be carried out to ensure the product is biocompatible with the delivery system. Such testing should evaluate cell viability and activity, cell adhesion to the device, and device integrity. “Because biologics can aggregate and adhere more easily at low flow rates, the worst-case delivery rate for this test may differ from that used in the other preclinical tests,” the guidance warns, adding that each new delivery system–product combination must be tested, because of the extremely variable sensitivities that cell therapies can have to physical and chemical stimuli.
The guidance document is available at www.fda.gov/OHRMS/DOCKETS/98fr/FDA-2009-D-0132-gdl.pdf
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Oligonucleotide Analysis in Pharmaceutical Quality Control
January 14th 2025Melting point determination using ultraviolet-visible (UV-Vis) spectrophotometry can be used as a sequence-specific method for identifying therapeutic oligonucleotides in pharmaceutical quality control. This method offers a simple, highly selective approach to differentiate between isomers and ensure the integrity of oligonucleotide active pharmaceutical ingredients (APIs) and drug products.
